SCHEMBL25593141

SCHEMBL25593141

Cc1ncc(N)cc1-c1cccc(Cl)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 1/20 0.53
TDO2 P48775 1/20 0.50
ADORA2A P29274 1/20 0.49
ADORA1 P30542 1/20 0.49
IRAK4 Q9NWZ3 1/20 0.47
RAB9A P51151 3/20 0.44
NPC1 O15118 2/20 0.44
IKBKE Q14164 1/20 0.44
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
USP7 Q93009 1/20 0.43
MAP4K4 O95819 2/20 0.43
LMNA P02545 2/20 0.43
MAPT P10636 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ESR2 Q92731 1/20 0.42
FYN P06241 1/20 0.42
PTPN11 Q06124 1/20 0.41
NUDT1 P36639 1/20 0.41
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14923566 0.81 IRAK4 (0.46) TDO2ADORA1IRAK4RAB9ANPC1
SCHEMBL16043752 0.80 DHFR (0.49) DHFRTDO2ADORA2AADORA1RAB9A
SCHEMBL25983849 0.79 RAF1 (0.38) IRAK4
SCHEMBL25593070 0.77 IRAK4 (0.41) ADORA2AADORA1IRAK4
SCHEMBL25983842 0.75 MAPT (0.49) DHFRTDO2ADORA2AADORA1RAB9A
SCHEMBL25593140 0.75 PLA2G7 (0.54) DHFRTDO2ADORA2AADORA1RAB9A
SCHEMBL17594940 0.75 RAF1 (0.42) ADORA2AADORA1IRAK4RAB9ANPC1
SCHEMBL25699202 0.75 RAF1 (0.39) DHFRTDO2IRAK4USP7FYN
SCHEMBL2131570 0.74 DHFR (0.51) DHFRTDO2ADORA2AADORA1MAP4K4
SCHEMBL25699095 0.73 IRAK4 (0.41) DHFRADORA2AIRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727922-A1 DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF Deciphera Pharmaceuticals, LLC (US) 2026-04-22 EP disclosed
WO-2024263460-A1 DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC (US) 2024-12-26 WO disclosed
US-20230357179-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-11-09 US disclosed
US-20230357179-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-11-09 US disclosed
US-20230257352-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-08-17 US disclosed
US-20230257352-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-08-17 US disclosed
WO-2023108108-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC (US) 2023-06-15 WO disclosed
WO-2023108103-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC (US) 2023-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357179-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF BRAF, RAF1, ARAF DHFR 815/4885TDO2 4178/4885ADORA2A 4133/4885
US-20230257352-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF BRAF, RAF1, ARAF DHFR 815/4885TDO2 4178/4885ADORA2A 4133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.